BHV 5000
Alternative Names: BHV-5000Latest Information Update: 28 Jan 2025
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Biohaven Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Complex regional pain syndromes; Major depressive disorder; Neurological disorders; Neuropathic pain; Rett syndrome
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for research development in Major depressive disorder in USA (PO)
- 28 Jan 2025 No recent reports of development identified for research development in Neuropathic-pain in USA (PO)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Rett syndrome(In volunteers) in USA (PO)